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Blood pressure, low-density lipoprotein cholesterol (LDL-C), and glycemia (for microvascular 
disease) represent the triumvirate of targets for managing vascular risk in type 2 diabetes.1 Novel 
treatments that substantially lower LDL-C levels,2,3 or that improve glucose control,4–6 can 
provide additional vascular risk reduction. Despite these advances in best care, however, an 
unacceptably high residual cardiovascular risk persists. Therefore, therapeutic interventions 
aimed at additional targets are needed. 
 
A key contender to address the enigma of residual vascular risk is the nuclear receptor 
peroxisome proliferator-activated receptor alpha (PPARα). PPARα, which is predominantly 
expressed in metabolically active tissues, pivotally regulates key metabolic and inflammatory 
pathways.7,8 Critical to this role is the ability of PPARα to exert either positive or negative 
control over the expression of genes involved in fatty acid oxidation, lipoprotein metabolism, 
and inflammation.  
 
Like other nuclear receptors, activation of PPARα requires binding of an agonist, either 
endogenous (such as fatty acids) or synthetic, to the ligand binding domain of the receptor. This 
ligation allows the activated PPARα to form a heterodimer with a partner nuclear receptor, 
retinoid X receptor (RXR), triggering a conformational change which stabilizes the ligand 
binding domain. This PPARα-RXR complex then binds to specific DNA sequences in the 
promoter region (the PPAR receptor response element) of target genes, promoting their 
expression. The PPARα-RXR complex can also bind to repressor proteins which inhibit the 
expression of other genes.9,10 The recruitment of a number of cofactors facilitates both processes, 
ensuring a ‘transcriptionally active’ PPAR complex. These cofactors can either activate 
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transcription of target genes (coactivators) or mediate repression of other genes (corepressors).11 
To date, 38 cofactors that bind to PPAR have been identified, including those involved in the 
activation of genes encoding lipoprotein lipase and apolipoprotein (apo) C-III, which regulate 
triglyceride-rich lipoprotein metabolism, and apo A-I, A-II, and the adenosine triphosphate-
binding cassette transporters A1 and G1, involved in high-density lipoprotein (HDL) 
metabolism. Other cofactors mediate the repression of pro-inflammatory genes, or genes 
influencing intracellular metabolism and oxidative stress.8,11  
 
This mode of action of PPARα exerts pleiotropic biological actions likely to benefit the milieu of 
risk factors in type 2 diabetes.12 Increases in HDL production, very-low-density lipoprotein 
(VLDL) clearance and LDL particle size, together with downstream decreases in VLDL 
production, and LDL particle concentration, illustrate a key role for PPARα agonism in 
managing atherogenic dyslipidemia (high plasma triglycerides, low HDL cholesterol, small, 
dense LDL particles, and elevated apo B and C-III), characteristic of type 2 diabetes. Anti-
inflammatory effects limit local cellular inflammation and thrombogenesis, pathways linked to 
cardiovascular complications.12 Promotion of beta-oxidation and the mitochondrial tricarboxylic 
acid cycle ameliorate adverse intracellular metabolic changes, including effects on glucose 
homeostasis.12 This multimodal pharmacological profile implies that PPARα agonism has the 
potential to reduce atherosclerotic cardiovascular disease (ASCVD) risk in type 2 diabetes.  
 
Clinicians are, however, well aware that current PPARα agonists – fibrates – have proven 
underwhelming in cardiovascular outcome studies. Their administration has failed to show 
definitive clinical benefit against a background of best evidence-based treatment including statin 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
therapy.13 Moreover, classical fibrates can have safety issues such as elevation in serum 
creatinine, which although reversible,14 raise concerns among practitioners. Certain currently 
available fibrates interact with other drugs, for example gemfibrozil can cause hazard when 
combined with statins.15 Understanding the mode of action of PPARα, however, suggests 
avenues for the development of novel selective PPARα agonists that might overcome the 
deficiencies of the fibrates, and also benefit metabolic diseases with an underlying inflammatory 
component. 
 
Such thinking underlies the SPPARMα (Selective Peroxisome Proliferator-Activated Receptor 
Alpha Modulator) concept, which aims to maximize favourable effects associated with PPARα 
activation while simultaneously limiting the propensity for unwanted effects.16 To this end, the 
large lipid-binding pocket of PPARα provides numerous potential contact points capable of 
triggering different conformational changes, each potentially associated with a unique cofactor 
recruitment pattern, and a specific profile of biological effects.17 Thus, modulating the cofactor 
recruitment pattern provides the opportunity to improve the benefit versus risk profile of the 
agonist, in particular overcome issues with renal and hepatic safety (Figure), key deterrents of 
previous selective PPARα prototypes.18  
 
The SPPARMα concept provides a highly attractive basis for the development of novel agents 
that act at multiple targets relevant to vascular risk in cardiometabolic disease. Insights into the 
role of PPARα in the hepatic inflammatory process may also offer therapeutic potential in non-
alcoholic fatty liver disease,19 not only implicated in the development of type 2 diabetes, but also 
a marker of ASCVD risk. The ultimate question is whether SPPARMα agonism provides a 
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multifaceted solution to the enigma of residual vascular risk in type 2 diabetes; for this we await 
results from the cardiovascular outcomes study, PROMINENT.20 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
Acknowledgements 
Role of the funding source: There were no sources of funding. 
Author contributions: JCF and RDS drafted the comment; all authors reviewed and finalised 
the comment. 
Declaration of interests 
J-C Fruchart reports personal fees from Kowa Company; RD Santos reports personal fees from 
Amgen, AstraZeneca, Merck, Akcea, Sanofi/Regeneron, Biolab, Esperion, Kowa, and Novo-
Nordisk; S Yamashita reports grants and personal fees from Kowa Company, Ltd., Otsuka 
Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Bayer Yakuhin, Ltd., MSD K.K., Takeda 
Pharmaceutical Company, Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Astellas Pharma Inc., 
Daiichi-Sankyo Company, Ltd., Astra Zeneka K.K., Kaken Pharmaceutical Co., Ltd., grants 
from Nippon Boehringer Ingelheim Co., Ltd., National Institute of Biomedical Innovation, 
Kyowa Medex Co., Ltd., Mochida Pharmaceutical Company, Ltd., Hayashibara Co., Ltd., Teijin 
Pharma Limited and Kissei; and personal fees from Ono Pharmaceutical Company, Ltd., 
Skylight Biotec, Inc., Pfizer, Astellas Amgen, Sanofi, and Aegerion In addition, M Yamashita 
has a patent PCT/JP2016/074402 (Assisting Method for the Diagnosis of Type III 
Hyperlipidemia) pending to Fujirebio & Osaka University, a patent PCT/JP2017/038766 
(Method for Selecting Subject Needing Treatment for Dyslipidemia and Reagent for Such 
Selection) pending to Osaka University & Kyowa Medex Co., Ltd., and a patent 
PCT/JP2017/038715 (Method for Measuring Oxidized High-Density Lipoprotein) pending to 
Osaka University & Kyowa Medex Co., Ltd. P Libby reports a research grant from Novartis and 
honoraria as a scientific advisory board member for Dalcor Pharmaceuticals. He also provides 
unpaid consultancy for Amgen, AstraZeneca, Ionis Pharmaceuticals, Kowa Pharmaceuticals, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
Pfizer, Sanofi-Regeneron, XBiotech Inc., Corvidia Therapeutics, IFM Therapeutics, Olatec 
Therapeutics, Medimmune and Esperion Therapeutics. 
 
References 
1. Piepoli MF, Hoes AW, Agewall S,  et al. 2016 European Guidelines on cardiovascular disease 
prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology 
and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by 
representatives of 10 societies and by invited experts) Developed with the special contribution of 
the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 
2016; 37: 2315–81. 
2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients 
with cardiovascular disease. N Engl J Med 2017; 376: 1713–22. 
3. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute 
coronary syndrome. N Engl J Med 2018; 379: 2097–107. 
4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and 
mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–28. 
5. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in 
type 2 diabetes. N Engl J Med 2017; 377: 644–57. 
6. Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 
receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 
2018; 6: 105–13. 
7. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by 
peroxisome proliferators. Nature 1990; 347: 645–50. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
8. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators 
regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. 
Curr Opin Lipidol 1999; 10: 245–57. 
9. Gervois P, Fruchart JC, Staels B. Drug Insight: mechanisms of action and therapeutic 
applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract 
Endocrinol Metab 2007;, 3:145–56. 
10. Blanquart C, Mansouri R, Paumelle R, Fruchart JC, Staels B, Glineur C. The protein kinase 
C signaling pathway regulates a molecular switch between transactivation and transrepression 
activity of the peroxisome proliferator-activated receptor alpha. Mol Endocrinol 2004; 18: 1906–
18. 
11. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and 
atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004; 94:1168–78. 
12. Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads 
of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009; 205: 1–8. 
13. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination 
lipid therapy in type 2 diabetes mellitus. N Eng J Med 2010; 362: 1563–74. 
14. Mychaleckyj JC, Craven T, Nayak U, et al. Reversibility of fenofibrate therapy-induced renal 
function impairment in ACCORD type 2 diabetic participants. Diabetes Care 2012; 35: 1008–
14. 
15. Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: 
evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 2006; 5: 145–
56. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
16. Fruchart JC. Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): 
the next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc 
Diabetol 2013; 12: 82. 
17. Yamamoto Y, Takei K, Arulmozhiraja S, et al. Molecular association model of PPARα and 
its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα. Biochem 
Biophys Res Commun 2018; 499: 239–45. 
18. Nissen SE, Nicholls SJ, Wolski K, et al. Effects of a potent and selective PPAR-alpha agonist 
in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled 
trials. JAMA 2007; 297: 1362–73. 
19. Lim S, Taskinen MR, Borén J. Crosstalk between nonalcoholic fatty liver disease and 
cardiometabolic syndrome. Obes Rev 2019; 20: 599–611.   
20. Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the Pemafibrate to 
Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes 
(PROMINENT) study. Am Heart J 2018; 206: 80–93. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
Figure. Schematic illustrating the SPPARMα (Selective Peroxisome Proliferator-Activated Receptor Alpha 
Modulator) concept.  
Modulating the unique cofactor recruitment pattern associated with binding of the selective agonist to PPARα 
provides the opportunity to improve the benefit versus risk profile compared with currently available fibrates.  
Abbreviations: apo apolipoprotein; HDL-C high-density lipoprotein cholesterol; TG triglycerides 
Figure design by J-C Fruchart. 
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